U.S.-headquartered Alloy Therapeutics, a biotech firm focused on expanding access to drug discovery tools, said it has signed a memorandum of understanding with Serbia's state-owned operator of the ...

A former Pfizer scientist was subpoenaed Monday by House Republicans over allegations that there was a conspiracy among senior executives at the pharma company to “deliberately slow down&#822… ...

The House Judiciary Committee has subpoenaed a former Pfizer executive who is considered central to its investigation into an allegation that clinical testing related to the development of the ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment analysis of PFE stock.

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2025 dividend on the company’s common stock, payable Septe ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s move for a lot less money.

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing that his team went through individual scans and interviewed investigators ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely reflecting existing concerns.

A year after an old tweet caused new problems, pandemic-era posts linked to Pfizer have again been found to have brought discredit on the industry.

Pfizer is licensing a promising investigational cancer medicine from a smaller company. This move improves the drugmaker's already attractive oncology pipeline. Pfizer should eventually bounce ...

Pfizer is in-licensing a bispecific antibody drug for cancer that China-based 3SBio designed to block the proteins PD-1 and VEGF. The deal puts the pharmaceutical giant in a growing group of ...